Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with ceftobiprole may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporting polypeptide (OATP) 1B1 and/or OATP1B3. The proposed mechanism is decreased clearance due to ceftobiprole-mediated inhibition of OATP1B1 and/or OATP1B3.

MANAGEMENT: Concomitant use of ceftobiprole with drugs that are substrates of OATP1B1 and/or OATP1B3 is not recommended. Clinical and laboratory monitoring may be appropriate whenever ceftobiprole is added to or withdrawn from therapy with these drugs. Dosage adjustments may be considered if an interaction is suspected. Patients should be monitored for the development of adverse effects.

Pravastatin may cause liver problems and using it with substantial quantities of ethanol (alcohol) may increase that risk. You should limit the use of alcohol while being treated with these medications. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.